Easywell Biomedicals, Inc. (TPEX:1799)
Taiwan
· Delayed Price · Currency is TWD 38.65
+0.60 (1.58%)
Apr 29, 2026, 10:31 AM CST
Easywell Biomedicals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 597.41 | 540.44 | 271.63 | 178.9 | 197.28 | Upgrade
|
| Revenue Growth (YoY) | 10.54% | 98.96% | 51.84% | -9.32% | -26.29% | Upgrade
|
| Cost of Revenue | 317.11 | 241.04 | 100.91 | 102.58 | 146.85 | Upgrade
|
| Gross Profit | 280.31 | 299.4 | 170.72 | 76.31 | 50.43 | Upgrade
|
| Selling, General & Admin | 113.02 | 94.88 | 61.96 | 28.16 | 24.15 | Upgrade
|
| Research & Development | 237.14 | 274.33 | 271.5 | 209.41 | 238.14 | Upgrade
|
| Operating Expenses | 347.51 | 374.19 | 333.46 | 237.57 | 262.29 | Upgrade
|
| Operating Income | -67.2 | -74.79 | -162.74 | -161.26 | -211.86 | Upgrade
|
| Interest Expense | -22.48 | -21.16 | -19.26 | -17.25 | -16.08 | Upgrade
|
| Interest & Investment Income | 2.94 | 4.94 | 3.42 | 2.18 | 1.18 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.23 | 2.28 | 7.5 | 7.53 | -1.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.72 | 0.34 | 1.17 | 0.46 | 57.99 | Upgrade
|
| EBT Excluding Unusual Items | -75.79 | -88.39 | -169.91 | -168.34 | -169.91 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.43 | 0.16 | - | 0.07 | 0.01 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.18 | 0.03 | - | - | 0.24 | Upgrade
|
| Other Unusual Items | - | -0.09 | - | - | - | Upgrade
|
| Pretax Income | -75.18 | -88.29 | -169.91 | -168.28 | -169.66 | Upgrade
|
| Income Tax Expense | 0.3 | 0.16 | 0.26 | 0.12 | 0.85 | Upgrade
|
| Earnings From Continuing Operations | -75.48 | -88.44 | -170.17 | -168.39 | -170.51 | Upgrade
|
| Net Income to Company | -75.48 | -88.44 | -170.17 | -168.39 | -170.51 | Upgrade
|
| Minority Interest in Earnings | 2.34 | -9.02 | 25.35 | 7.39 | 20.12 | Upgrade
|
| Net Income | -73.14 | -97.47 | -144.82 | -161 | -150.39 | Upgrade
|
| Net Income to Common | -73.14 | -97.47 | -144.82 | -161 | -150.39 | Upgrade
|
| Shares Outstanding (Basic) | 124 | 120 | 114 | 114 | 106 | Upgrade
|
| Shares Outstanding (Diluted) | 124 | 120 | 114 | 114 | 106 | Upgrade
|
| Shares Change (YoY) | 3.02% | 5.03% | 0.05% | 7.48% | 14.08% | Upgrade
|
| EPS (Basic) | -0.59 | -0.81 | -1.27 | -1.41 | -1.41 | Upgrade
|
| EPS (Diluted) | -0.59 | -0.81 | -1.27 | -1.41 | -1.41 | Upgrade
|
| Free Cash Flow | 109.37 | -171.53 | -169.17 | -60.99 | -136.02 | Upgrade
|
| Free Cash Flow Per Share | 0.88 | -1.43 | -1.48 | -0.53 | -1.28 | Upgrade
|
| Gross Margin | 46.92% | 55.40% | 62.85% | 42.66% | 25.56% | Upgrade
|
| Operating Margin | -11.25% | -13.84% | -59.91% | -90.14% | -107.39% | Upgrade
|
| Profit Margin | -12.24% | -18.04% | -53.31% | -90.00% | -76.23% | Upgrade
|
| Free Cash Flow Margin | 18.31% | -31.74% | -62.28% | -34.09% | -68.95% | Upgrade
|
| EBITDA | -2.48 | -22.19 | -121.01 | -116 | -160.42 | Upgrade
|
| EBITDA Margin | -0.41% | -4.11% | -44.55% | -64.84% | -81.32% | Upgrade
|
| D&A For EBITDA | 64.72 | 52.6 | 41.73 | 45.26 | 51.45 | Upgrade
|
| EBIT | -67.2 | -74.79 | -162.74 | -161.26 | -211.86 | Upgrade
|
| EBIT Margin | -11.25% | -13.84% | -59.91% | -90.14% | -107.39% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.